ESTRO 38 Abstract book

S637 ESTRO 38

chemotherapy, mainly concurrent (88.4%). 29 (41.5%) patients received induction chemotherapy. 25 (35.7%) patients received neoadyuvant and adjuvant chemotherapy. Response rate 8 weeks after ending radiotherapy were: complete response 65.7%, partial response 29.9%, stable disease 1.5% and progressive disease 2.9%. At a median follow-up of 62 months (range 4-136), 9 patients experienced local regional failure and distant metastasis occurred in 12 patients. 1-ys, 3-ys and 5- ys Disease Free Survival were 90%, 79% and 67%, respectively while 1-ys, 3-ys and 5- ys Overall Survival were 98%, 86% and 74% respectively. The most common late adverse effects were: xerostomia, dysphagia, and fibrosis. Grade 3 dental damage and xerostomia occurred in 1 case (16%) and 1 (2.1%) respectively. No case of grade IV toxicity was observed. Conclusion IMRT-SIB combined with concurrent chemotherapy or plus neoadjuvant or adyuvant chemotherapy resulted in promising rates of local regional control with acceptable rates of late side effects in patients with nasopharyngeal carcinoma. EP-1149 Albumin-to-alkaline phosphatase ratio in nasopharyngeal cancer: a propensity score matching analysis J.S. Kim 1 , B. Keam 2 , D.S. Heo 2 , D.H. Han 3 , C. Rhee 3 , J. Kim 4 , K.C. Jung 5 , H. Wu 1 1 Seoul National University Hospital, Department of Radiation Oncology, Seoul, Korea Republic of ; 2 Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea Republic of ; 3 Seoul National University Hospital, Department of Otorhinolaryngology, Seoul, Korea Republic of ; 4 Seoul National University Hospital, Department of Radiology, Seoul, Korea Republic of ; 5 Seoul National University Hospital, Department of Pathology, Seoul, Korea Republic of Purpose or Objective We first analyzed the prognostic power of albumin-to- alkaline phosphatase ratio (AAPR) before radical radiotherapy (RT) in non-metastatic nasopharyngeal The records of 170 patients with biopsy-proven, non- metastatic NPC treated by radical RT between 1998 and 2016 at our institution were retrospectively reviewed. Median follow-up duration was 50.6 months. All patients received intensity-modulated RT and cisplatin based chemotherapy before, during, or after RT. The major treatment of patients were based on concurrent chemoradiotherapy (92.4%). The AAPR was calculated by the last value of both albumin and alkaline phosphatase within 1 month immediately preceding RT. The optimal cut-off level of AAPR was determined by using Cutoff Finder , a web-based system. Propensity score matching (PSM) analysis was performed. Results The optimal cut-off level of AAPR was 0.4876. After PSM analysis of whole cohort, an AAPR was not related to survival outcomes. In PSM analysis for patients with locoregionally advanced nasopharyngeal cancer (LA-NPC), an AAPR ≥0.4876 was related to better overall survival (OS), progression free survival (PFS) and locoregional relapse free survival (LRRFS) (OS, HR: 0.341, 95% CI: 0.144-0.805, p=0.014; PFS, HR: 0.416, 95% CI: 0.189- 0.914, p=0.029; LRRFS, HR: 0.243, 95% CI: 0.077-0.769, p=0.016, respectively). Conclusion The AAPR, inexpensive and readily derived from a routine blood test, could be an independent prognostic factor for patients with LA-NPC. And it might help physicians determine treatment plans by identifying the patient's current status. Future prospective clinical trials to validate its prognostic value are needed. cancer(NPC) patients. Material and Methods

Median prescribed total dose was 70,4 Gy RBE (range 66- 70,4 Gy RBE) in 15-16 fractions (median 16 fractions) of 4,4 Gy RBE for CIRT, and 74 Gy RBE (range 70-74 Gy RBE) in 35-37 fractions (median 35 fractions) of 2 Gy RBE for PT. Clinical outcome (local control -LC- and overall survival -OS-) and toxicity profile (according to Common Terminology Criteria Adverse Events -CTCAE V4.03- scale) were evaluated Results The median follow-up was 34 months (range, 5-70 months). Only 1 patient had local progression 24 months after the end of the treatment. The LC rate was 97%. The 1-year, 3-year and 5-year LC rates were 100%, 96% and 96% respectively; the corresponding OS rates were 97%, 93% and 93% respectively (Fig 1). The toxicity profile was favorable. No pts developed late G4 treatment-related toxicity. G3 late toxicity occurred in 2 (5.7%) of pts: 1 case of hearing impairment and 1 case of ocular toxicity (sight reduction)

Conclusion particle therapy is a safe and effective treatment in pts with chondrosarcoma of the skull-base EP-1148 Long-term outcome of IMRT with simultaneous integrated boost in nasopharyngeal carcinoma I. Linares 1 , M. Taberna 2 , J. Nogués 3 , R. Mesía 2 , D. Najjari 1 , J. Mases 1 , I. Guix 1 , M. Plana 2 , A. Lozano 1 1 Institut Català d'Oncologia, Radiation Oncology, Barcelona, Spain ; 2 Institut Català d'Oncologia, Medical Oncology, Barcelona, Spain ; 3 Hospital Universitario de Bellvitge, Otorhinolaryngology, Barcelona, Spain Purpose or Objective To report the long-term clinical outcomes of nasopharynx cancer patients treated with IMRT-simultaneous integrated boost (SIB) in a non-endemic area. Material and Methods We retrospectively reviewed the data from 70 patients with non-metastatic nasopharyngeal carcinoma who received IMRT-SIB from January 2007 to December 2015. High-risk PTV was treated with a daily dose of 2.12 Gy and a total dose of 69.96Gy. Low-risk PTV was treated with a daily dose of 1.64 Gy and a total dose of 54.12 Gy. Patients received concurrent chemotherapy during the course of the RT with intravenous administration of 100 mg/m 2 cisplatin every 3 weeks or 30-40 mg/m 2 weekly. The induction chemotherapy regimen was TPF (docetaxel/cisplatin/5-fluorouracil) or PF every 3 weeks for 2-3 cycles. Post-radiation adjuvant chemotherapy with PF (two-three cycles) also was used as option treatment. We analyzed the survival outcome and late toxicity outcome (scale CTCAE v4.03). Results 73% of all cases were men; median age was 51 years (range 15 - 79). Non-keratinizing carcinoma was the most common histological type (76.9%) and EBV was positive in 44 (62.9%). According to the AJCC 7 th Edition staging system 94.3% of cases were locally advanced disease, stage III-IVB. Only 7 patients (10%) were treated exclusively with RT, while the rest received